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ROBERT. E. PETR ES, M .D., Associate Professor of Obstetrics and Gynecology 
The diagnosis of chromosomal and metabolic 
abnormalities by mid-trimester amniocentesis is now 
an established part of antenatal care. Jacobson pub-
lished the first use of this technique in 1967, 1 followed 
in 1968 by Nadler. 2 By 1974, over 3,000 pregnancies 
had been studied permitting the prenatal diagnosis of 
a wide variety of chromosomal anomalies and more 
than 60 different inborn errors of metabolism during 
the second trimester of pregnancy at a time when 
termination of the pregnancy can be safely performed 
if an abnormality is detected . During this period, the 
National Institute of Child Health and Human De-
velopment established a Nation al Registry for am-
niocentesis in an attempt to document the safety and 
accuracy of this technique. Its report was published 
in 1975 and dealt with a comparison of 1,040 preg-
nancies studied by mid-trimester amniocentesis and 
992 matched control pregnancies.3 The conclusions 
from the study were that mid-trimester amniocentesis 
was a safe procedure when performed by a qualified 
physician and that the accuracy rate of antenatal 
genetic diagnosis was 99.4%. Since 1975, the use of 
this procedure has become almost routine in preg-
nancies at risk for identifiable genetic abnormalities 
because of maternal age or family history. It should 
be emphasized that in the vast majority of cases pre-
natal genetic diagnosis is a life-saving procedure. 
Many women who are at high risk would not choose 
to continue their pregnancy unless they could be as-
sured that there is no detectable fetal abnormality . In 
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the series of 1,040 amniocentesis procedures men-
tioned above, only 34 abnormalities were detected; of 
these, 27 women elected to terminate their pregnancy. 
In addition, 11 male fetuses were identified among 
the 21 at risk for X-linked disorders and 8 of these 11 
women elected to terminate their pregnancies. 
Because the number of qualified laboratories is 
limited, the cases which can be studied must be re-
stricted to certain high-risk categories. The largest 
group of pregnant women at increased risk of pro-
ducing an abnormal child are patients over 35 years 
of age. It is well established that as the mother ages , 
the incidence of nondisjunction in her gametes in-
creases. Table I shows the relation between the in-
cidence of trisomy 21 and maternal age. Another 
indicator of the effect of maternal age is that while 
only 13% of pregnancies occur in mothers over 35 
years old , these pregnancies produce 51 % of all cases 
of Down syndrome. Recent studies employing nor-
mal chromosomal markers4 have clearly shown that 
the extra chromosome in this syndrome is not in-
variably maternal in origin. If only those cases in 
which the nondisjunction occurred in the mother 
were considered, it seems likely that a more striking 
relationship to the maternal age would be observed . 
Age 35 is considered by many to be the maternal age 
at which the risk is sufficiently great to recommend 
amniocentesis, but this figure is obviously somewhat 
arbitrary . 
The second largest group of patients for whom 
antenatal diagnosis is recommended are women who 
have already had a child with trisomy 21 . The risk of 
producing another mongoloid child in this group is 
I% to 2%. Needless to say, these mothers are also 
extremely anxious about a recurrence, and in most 
cases the results of the cytogenetic _analysis serve to 
all ay their fears. 
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TABLE I 
Relation of Maternal Age and Chromosome Abnormalities 
Maternal 
Age 
10-14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
Distribution 
of mothers 
of children Risk of chromosome 
Distribution with abnormality by 
o f tota l chromosome age group 
sa mple abnormality 
(%) (%) N Percentage 
0.4 0 0/ 19 
11.0 5.3 1/ 490 0.20 
34.4 42.4 8/ 1531 0.52 
32.0 21.2 4/ 1423 0.28 
14.3 5.3 1/ 635 0.16 
6.2 21.2 4/ 277 1.44 
1.4 5.3 1/ 62 1.61 
.07 0 0/ 3 
Distribution of materna l ages. N = number of abnormalities 
di vided by number in age group. 
A small group of patients at considerable risk for 
chromosomally abnormal children are families in 
which one of the parents carries a chromosomal 
translocation . In these cases, the risk varies depend-
ing on the translocation . For example, in the case of a 
t(2 l ;21) carrier, the risk of bearing a mongoloid child 
is I 00%; while in the case of the more common DI G 
translocation t( 15;2 l ), the risk of producing a child 
with translocation Down syndrome varies from 
about 10% to 30% depending upon whether the father 
or the mother is the translocation carrier. This trans-
location group is responsible for "familial mon-
golism" and is fortunately quite rare . Of all mongol-
oid children, 2% to 3% are of the translocation type; 
of these, only about half are familial and the remain-
der are de novo translocations. 
Approximately 150 genetic diseases have been 
recognized which show an X-linked pattern of trans-
mission, and many such as the X-linked hemophilias, 
Duchenne-type muscular dystrophy, and agam-
maglobulinemia are associated with serious or even 
lethal disease . X-linked disorders only affect male 
offspring, although carrier females may occasionally 
show mild symptoms. Specific intrauterine diagnosis 
is not yet possible for most X-linked traits; however, 
since it is possible to diagnose the sex of the child in 
utero, carrier females can avoid giving birth to addi-
tional affected males if they are willing to carry only 
female infants to term . Some couples find this an 
acceptable method of completing their families with-
out the fear of a recurrent abnormality; others do 
not. In any case the decision about whether or not to 
use this approach is made by the parents themselves. 
The dilemma of terminating potentially normal preg-
nancies would be solved if specific tests were available 
to diagnose each X-linked disease. Currently, this is 
possible only for a relatively few X-linked diseases in 
which the specific enzymatic defect has been identi-
fied . These conditions include Hunter syndrome, the 
Lesch-Nyhan syndrome, and Fabry disease. In addi-
tion, approximately 40 rare autosomal recession 
traits are known in which the enzyme defect can be 
detected with varying reliabilities in fibroblasts. 
The last category of patients at risk for specific 
fetal abnormalities are those who have had a previous 
child with a neural tube defect (anencephaly, enccph-
alocele, meningomyelocele, and spin a bifida ). As a 
group, the recurrence rate for any of these disorders 
is about 5%.5 These abnormalities are not chromo-
somal defects, therefore, the fetal karyotype is not 
useful. However , it has been well proven that the level 
of alpha-fetoprotein in the amniotic fluid at 16 to 18 
weeks gestation correlates with these defects; a high 
level of alpha-fetoprotein (greater than 5 standard 
deviations above normal) is diagnostic of an open 
neural tube defect. Amniography, fetoscopy, and ul-
trasound can also be utilized to document these ab-
normalities. 
In summary, the general indications for amnio-
centesis for prenatal diagnosis are as follows: 
I. Maternal age greater than 35 years at time of 
conception. 
2. History of a previous child with Down syn-
drome or any other trisomy . 
3. Documented chromosomal translocation in 
either parent. 
4. Previous child with a serious inherited X-
linked disease or an autosomal genetic disease 
that can be detected prenatally. 
5. Previous child with a midline neurologic de-
fect. 
Table 2 is a summary of the indications for am-
niocentesis performed at MCV since 1973. 
Patients who have been counseled and have a 
definite indication for prenatal genetic diagnosis, and 
who have given their informed consent, are first 
scheduled for an ultrasound examination. This non-
invasive scanning procedure can locate the placenta, 
identify the best area for the amniocentesis, and rule 
out twin gestations. It also accurately measures the 
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TABLE 2 
Indications for Prenatal Diagmisis at MCV 
(9-1-73 to 7-1-77) 
28 Previous trisom y 21 
77 Maternal age 40 yr o r greater 
65 Maternal age 35 yr to 39 yr 
8 Close reiati ve with trisomy 21 
Previous child with hemophili a A 
I Previous spina bifida + cleft palate 
IO Previous spin a bifida or hydrocephalus or meningocele 
22 Previous anencephalic 
I Previous Potter syndrome 
2 Anophthalmia 
Previo us GI G translocation carrier 
Previous DIG translocation carrier 
Elevated maternal creatine phosphokinase 
Previous child with Sandhoff disease 
Four previous spontaneous a bortions 
Previous trisom y 18 
Previous triso my 13 
Previo4s XX / XO mosaics 
I Three previous "retarded" children 
2 Previous child with "multiple defects" 
fetal head to document fetal age. After the ultrasound 
procedure, the patient's abdomen is prepared and 
under sterile conditions the amniocentesis is per-
formed by an experienced obstetrician. The amnio-
centesis procedure involves the introduction of a 
small bore needle through the mother's abdominal 
wall into the uterus and amniotic cavity under local 
anesthesia. The ultrasound examination ilids in se-
lecting the proper placement of the needle to avoid 
the b<1by and to locate the amniotic fluid . Twenty 
milliliters of fluid are withdrawn and the needle re-
moved . Most patients have no ill effects from the 
procedure and can go home shortly after it is per-
formed . The optimum time to obtain the amniotic 
fluid is from 15 to 16 weeks gestation . 
Preliminary results are usually available within 
three weeks of the procedure and the final report is 
issued one to two weeks later. 
Since most of the patients have a rate of below 
5% of bearing an affected child, the results are usually 
that the fetus has a normal chromosome com-
plement. This greatly relieves the parents' anxiety and 
allows them to have a happy prenatal course and 
enjoy ;i normal baby. If, however, a mongoloid fetus 
or a fetus with anencephaly is diagnosed, the parents 
are counseled and pregnancy termination suggested. 
This decision is left to the parents once the facts are 
presented to them, and even for those parents who 
TABLE 3 
Medical College of Virginia Results of Antenatal Diagnosis 
(9-1-73 to 7-1-77) 
R ESULTS 
92XXXX 
46XY 
46XX 
45XY-D-G + DI G 
45XO 
47XY + G 
47XX + G 
47XXX 
Normal alpha-fetoprotein 
Abnormal alpha-fetoprotein 
N UMBER 
104 
84 
I 
I 
2 
21 
I 
felt before the study that there would be no question 
of terminating the pregnancy if the fetus were abnor-
mal, the decision is a difficult one. 
As of July I, 1977, at MCV, three patients, of 
216 studied, have been diagnosed with trisomy 21 in 
utero. All three patients underwent therapeutic abor-
tion . In addition, the diagnosis of a fetus with Turner 
syndrome (45XO) was made and the parents elected 
to continue the pregnancy since the abnormality de-
tected was not life-threatening. Table 3 summarizes 
the results of the antenatal testing at MCV. 
The future of antenatal genetic diagnosis is an 
exciting one. Recent advances include the application 
of chromosomal banding te~hniques to identify 
subtle abnormalities and rearrangements; ultraso-
nography, using high resolution gray scale equipment 
to permit delineation of fetal soft tissue and skeletal 
anomalies; and fetoscopy , using a small fiberoptic 
instrument to view the fetus directly and observe its 
development. With the~e ad~ances in technology, it 
should be possible to enable even more women at 
high risk for genetically diseased offspring to bear 
healthy children. 
Table I is adapted from Science (169:495-497, 1970). 
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Recent Advances 1n Cytogenetic Technology 
for Antenatal Genetic Testing 
JUDITH A. BROWN, PH.D., ANNA CARR, ELIZABETH S. COOPER, AND 
DEBORAH W. HERITAGE, Cytogenetic Laboratory, Department of Human Genetics 
The examination of human chromosomes has 
been a part of the physician's laboratory armamen-
tarium since the correct diploid number of human 
chromosomes was established' and a method was 
developed2 for the in vitro growth of peripheral blood 
leukocytes to yield metaphase chromosomes. The 
discovery3 that on ultraviolet microscopy (UV), 
metaphase chromosomes stained with fluorochrome 
dyes displayed a characteristic pattern of bright and 
dull bands unique for a given pair of homologous 
chromosomes, was a major technological break-
through in human cytogenetics; for the first time, 
every chromosome in the karyotype could be un-
equivocally identified . Although the short storage life 
of fluorochrome-stained chromosomes and the costs 
of UV microscopy have limited the usability of fluo-
rescence banding, the introduction of one discrimina-
ting procedure quickly led to the development of an 
array of similar banding techniques for conventional 
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microscopy that yield comparable information. Some 
of these technical procedures depend on enzyme and/ 
or heat denaturation of the chromosomes, resultiri~ 
in the characteristic banding patterns seen by the 
trypsirt-Giemsa method,4 the 5M urea method,5 and 
the acid-saline-Giemsa technique.6 A typical human 
karyotype prepared from metaphase chromosomes 
treated with trypsin, stained with Giemsa, and photo-
graphed with brightfield photomicrographic tech-
niques is shown in Figure I. Careful examination of 
this karyotype reveals that each chromosome in the 
homologous pair has an array of dark and light 
bands identical with those of its homolog and that 
each homologous pair, autosomes number I to num-
ber 22, has a characteristic, easily identifiable band-
ing pattern. 
In order to establish a standardized nomencla-
ture to describe the chromosomes and chromosome 
regions, as revealed by the banding techniques, a 
committee of international experts in human cyto-
genetics met in Parls, France, in 1971.7 The com-
mittee retained the previously established designation 
of the short arm of the chromosome as "p" and the 
long arm as "q" and agreed to divide the chromo-
some arms into a number of regions according to the 
